Mosaic HIV-1 gag antigens can be processed and presented to human HIV-specific CD8+ T cells

Journal of Immunology

Volumn 186, Issue 12, 2011, Pages 6914-6924

  Ndhlovu, Zaza M ^a,b   Piechocka Trocha, Alicja ^a,b   Vine, Seanna ^a   McMullen, Ashley ^a   Koofhethile, Kegakilwe C ^c   Goulder, Phillip J R ^c,d   Ndung'u, Thumbi ^a,c   Barouch, Dan H ^a,e   Walker, Bruce D ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TETRAMER; VIRUS VACCINE;

ADENOVIRUS; ADENOVIRUS 26; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME ACTIVATION; ENZYME SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IN VITRO STUDY; MALE; MOSAIC VIRUS; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS REPLICATION;

ADENOVIRIDAE; AIDS VACCINES; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; GENE PRODUCTS, GAG; GENETIC VECTORS; HIV-1; HUMANS; SOUTH AFRICA; SPECIES SPECIFICITY; UNITED STATES;

EID: 79959565170     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1004231     Document Type: Article

References (47)

1. Virgin, H. W., and B. D. Walker. 2010. Immunology and the elusive AIDS vaccine. Nature 464: 224-231.
2. Walker, B. D., and D. R. Burton. 2008. Toward an AIDS vaccine. Science 320: 760-764.
3. Drake, J. W., and J. J. Holland. 1999. Mutation rates among RNA viruses. Proc. Natl. Acad. Sci. USA 96: 13910-13913.
4. de Oliveira, T., K. Deforche, S. Cassol, M. Salminen, D. Paraskevis, C. Seebregts, J. Snoeck, E. J. van Rensburg, A. M. Wensing, D. A. van de Vijver, et al. 2005. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21: 3797-3800. (Pubitemid 41535530)
5. Hraber, P. T., R. W. Leach, L. P. Reilly, J. Thurmond, K. Yusim, C. Kuiken; Los Alamos HIV database team. 2007. Los Alamos hepatitis C virus sequence and human immunology databases: an expanding resource for antiviral research. Antivir. Chem. Chemother. 18: 113-123.
6. Gaschen, B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Novitsky, B. Haynes, B. H. Hahn, T. Bhattacharya, and B. Korber. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360. (Pubitemid 34734202)
7. Le Gall, S., P. Stamegna, and B. D. Walker. 2007. Portable flanking sequences modulate CTL epitope processing. J. Clin. Invest. 117: 3563-3575.
8. Seifert, U., C. Marañón, A. Shmueli, J. F. Desoutter, L. Wesoloski, K. Janek, P. Henklein, S. Diescher, M. Andrieu, H. de la Salle, et al. 2003. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat. Immunol. 4: 375-379.
9. Beekman, N. J., P. A. van Veelen, T. van Hall, A. Neisig, A. Sijts, M. Camps, P. M. Kloetzel, J. J. Neefjes, C. J. Melief, and F. Ossendorp. 2000. Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site. J. Immunol. 164: 1898-1905. (Pubitemid 30108744)
10. Yang, O. O., P. T. Sarkis, A. Ali, J. D. Harlow, C. Brander, S. A. Kalams, and B. D. Walker. 2003. Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J. Exp. Med. 197: 1365-1375.
11. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, et al; Step Study Protocol Team. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-ofconcept trial. Lancet 372: 1881-1893.
12. Barouch, D. H., and B. Korber. 2010. HIV-1 vaccine development after STEP. Annu. Rev. Med. 61: 153-167.
13. Robb, M. L. 2008. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 372: 1857-1858.
14. Sekaly, R. P. 2008. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205: 7-12.
15. Finnefrock, A. C., X. Liu, D. W. Opalka, J. W. Shiver, D. R. Casimiro, and J. H. Condra. 2007. HIV type 1 vaccines for worldwide use: predicting in-clade and cross-clade breadth of immune responses. AIDS Res. Hum. Retroviruses 23: 1283-1292.
16. Frahm, N., D. C. Nickle, C. H. Linde, D. E. Cohen, R. Zuñiga, A. Lucchetti, T. Roach, B. D. Walker, T. M. Allen, B. T. Korber, et al. 2008. Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity. AIDS 22: 447-456. (Pubitemid 351317286)
17. McBurney, S. P., and T. M. Ross. 2009. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine 27: 4337-4349.
18. Yusim, K., W. Fischer, H. Yoon, J. Thurmond, P. W. Fenimore, G. Lauer, B. Korber, and C. Kuiken. 2010. Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. J. Gen. Virol. 91: 1194-1206.
19. Corey, L., and M. J. McElrath. 2010. HIV vaccines: mosaic approach to virus diversity. Nat. Med. 16: 268-270.
20. Santra, S., H. X. Liao, R. Zhang, M. Muldoon, S. Watson, W. Fischer, J. Theiler, J. Szinger, H. Balachandran, A. Buzby, et al. 2010. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 16: 324-328.
21. Barouch, D. H., K. L. O'Brien, N. L. Simmons, S. L. King, P. Abbink, L. F. Maxfield, Y. H. Sun, A. La Porte, A. M. Riggs, D. M. Lynch, et al. 2010. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 16: 319-323.
22. Fischer, W., S. Perkins, J. Theiler, T. Bhattacharya, K. Yusim, R. Funkhouser, C. Kuiken, B. Haynes, N. L. Letvin, B. D. Walker, et al. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13: 100-106.
23. Kosmrlj, A., E. L. Read, Y. Qi, T. M. Allen, M. Altfeld, S. G. Deeks, F. Pereyra, M. Carrington, B. D. Walker, and A. K. Chakraborty. 2010. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465: 350-354.
24. Wright, J. K., Z. L. Brumme, J. M. Carlson, D. Heckerman, C. M. Kadie, C. J. Brumme, B. Wang, E. Losina, T. Miura, F. Chonco, et al. 2010. Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J. Virol. 84: 10820-10831.
25. Kiepiela, P., A. J. Leslie, I. Honeyborne, D. Ramduth, C. Thobakgale, S. Chetty, P. Rathnavalu, C. Moore, K. J. Pfafferott, L. Hilton, et al. 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432: 769-775.
26. Abbink, P., A. A. Lemckert, B. A. Ewald, D. M. Lynch, M. Denholtz, S. Smits, L. Holterman, I. Damen, R. Vogels, A. R. Thorner, et al. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81: 4654-4663. (Pubitemid 46668663)
27. Brander, C., O. O. Yang, N. G. Jones, Y. Lee, P. Goulder, R. P. Johnson, A. Trocha, D. Colbert, C. Hay, S. Buchbinder, et al. 1999. Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences. J. Virol. 73: 10191-10198.
28. Goulder, P. J., C. Brander, Y. Tang, C. Tremblay, R. A. Colbert, M. M. Addo, E. S. Rosenberg, T. Nguyen, R. Allen, A. Trocha, et al. 2001. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412: 334-338. (Pubitemid 32694384)
29. Frahm, N., P. Kiepiela, S. Adams, C. H. Linde, H. S. Hewitt, K. Sango, M. E. Feeney, M. M. Addo, M. Lichterfeld, M. P. Lahaie, et al. 2006. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7: 173-178.
30. Johansen, P., P. Stamou, R. E. Tascon, D. B. Lowrie, and B. Stockinger. 2004. CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells. Eur. J. Immunol. 34: 91-97.
31. Hersperger, A. R., F. Pereyra, M. Nason, K. Demers, P. Sheth, L. Y. Shin, C. M. Kovacs, B. Rodriguez, S. F. Sieg, L. Teixeira-Johnson, et al. 2010. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 6: e1000917.
32. Betts, M. R., M. C. Nason, S. M. West, S. C. De Rosa, S. A. Migueles, J. Abraham, M. M. Lederman, J. M. Benito, P. A. Goepfert, M. Connors, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789. (Pubitemid 43882629)
33. Altfeld, M., E. T. Kalife, Y. Qi, H. Streeck, M. Lichterfeld, M. N. Johnston, N. Burgett, M. E. Swartz, A. Yang, G. Alter, et al. 2006. HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med. 3: e403.
34. Dinges, W. L., J. Richardt, D. Friedrich, E. Jalbert, Y. Liu, C. E. Stevens, J. Maenza, A. C. Collier, D. E. Geraghty, J. Smith, et al. 2010. Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J. Virol. 84: 4461-4468.
35. den Uyl, D., I. E. van der Horst-Bruinsma, and M. van Agtmael. 2004. Progression of HIV to AIDS: a protective role for HLA-B27? AIDS Rev. 6: 89-96.
36. Goulder, P. J., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, et al. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3: 212-217.
37. Feeney, M. E., Y. Tang, K. A. Roosevelt, A. J. Leslie, K. McIntosh, N. Karthas, B. D. Walker, and P. J. Goulder. 2004. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J. Virol. 78: 8927-8930.
38. Schneidewind, A., M. A. Brockman, R. Yang, R. I. Adam, B. Li, S. Le Gall, C. R. Rinaldo, S. L. Craggs, R. L. Allgaier, K. A. Power, et al. 2007. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 81: 12382-12393. (Pubitemid 350085852)
39. Harrer, T., M. Bäuerle, S. Bergmann, K. Eismann, and E. G. Harrer. 2005. Inhibition of HIV-1-specific T-cells and increase of viral load during immunosuppressive treatment in an HIV-1 infected patient with Chlamydia trachomatis induced arthritis. J. Clin. Virol. 34: 224-230.
40. Streeck, H., J. S. Jolin, Y. Qi, B. Yassine-Diab, R. C. Johnson, D. S. Kwon, M. M. Addo, C. Brumme, J. P. Routy, S. Little, et al. 2009. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J. Virol. 83: 7641-7648.
41. Navis, M., I. Schellens, D. van Baarle, J. Borghans, P. van Swieten, F. Miedema, N. Kootstra, and H. Schuitemaker. 2007. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J. Immunol. 179: 3133-3143.
42. Kloverpris, H., I. Karlsson, J. Bonde, M. Thorn, L. Vinner, A. E. Pedersen, J. L. Hentze, B. S. Andresen, I. M. Svane, J. Gerstoft, et al. 2009. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 23: 1329-1340.
43. Schaubert, K. L., D. A. Price, J. R. Salkowitz, A. K. Sewell, J. Sidney, T. E. Asher, S. E. Blondelle, S. Adams, F. M. Marincola, A. Joseph, et al. 2010. Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes. Eur. J. Immunol. 40: 1950-1962.
44. Liu, Y., J. McNevin, M. Rolland, H. Zhao, W. Deng, J. Maenza, C. E. Stevens, A. C. Collier, M. J. McElrath, and J. I. Mullins. 2009. Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses. J. Infect. Dis. 200: 1825-1833.
45. Mittendorf, E. A., C. E. Storrer, C. D. Shriver, S. Ponniah, and G. E. Peoples. 2005. Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides. Breast Cancer Res. Treat. 92: 85-93.
46. Kemball, C. C., C. D. Pack, H. M. Guay, Z. N. Li, D. A. Steinhauer, E. Szomolanyi-Tsuda, and A. E. Lukacher. 2007. The antiviral CD8+ T cell response is differentially dependent on CD4+ T cell help over the course of persistent infection. J. Immunol. 179: 1113-1121.
47. Ramsburg, E. A., J. M. Publicover, D. Coppock, and J. K. Rose. 2007. Requirement for CD4 T cell help in maintenance of memory CD8 T cell responses is epitope dependent. J. Immunol. 178: 6350-6358.